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Abstract
The Sleeping beauty (SB) system is a non-viral DNA based vector that has been used to stably integrate 
therapeutic genes into disease models. Here we report the SB system is capable of stably integrating the ΔR4-
R23/CTΔ micro-dystrophin gene into a conditionally immortal dystrophin deficient muscle cell-line, H2K SF1, a 
murine cell model for Duchenne muscular dystrophy. Genetically corrected H2K SF1 cells retained their 
myogenic properties in vitro. Moreover, upon transplantation ΔR4-R23/CTΔ micro-dystrophin expression was 
detected within mdx nu/nu mice. Our data suggests the SB system is an effective way of stably integrating 
therapeutic genes into myogenic cells.
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Introduction
Duchenne muscular dystrophy (DMD) is a lethal muscle wasting disease caused by mutations in the DMD gene 
which prevents the translation of a functional dystrophin protein. Dystrophin deficient muscle is particularly 
susceptible to contraction induced damage, leading to repetitive rounds of muscle degeneration and 
regeneration and eventually loss of muscle function. To date no treatment is available that halts or reverses the 
pathology of DMD. Gene replacement therapy is a potential treatment option for DMD, however a key factor for 
successful treatment is the stable integration of the exogenous gene into resident muscle stem cells, thus 
reducing the need for repeated treatment [1]. Whilst lentiviral vectors are effective in infecting and stably 
integrating therapeutic genes into cells ex vivo and in vivo, their high manufacture costs, integration site profile 
and potential to elicit an immune response hinder their application [2]. This highlights the need for alternative 
integrating vectors that can overcome these limitations. Sleeping Beauty (SB) is a Class II DNA transposon 
which has been used as a DNA vector for stably integrating therapeutic genes into a variety of disease models 
[3][4][5][6][7]. SB has shown to be a promising tool for non-viral gene therapy as it does not appear to elicit an 
immune response or have a hazardous integration profile and is therefore deemed safer than retroviral vectors 
[8][9][10].
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In light of the above, a proof of concept study was conducted to determine if the SB system was capable of 
stably integrating the ΔR4-R23/CTΔ micro-dystrophin gene [11], into a genome of a myogenic cell-line. As a 
target cell model we used a dystrophin deficient conditionally immortal muscle cell-line, H2K SF1 [12]. The cell-
line harbours a thermolabile T-antigen gene [13] which allows continuous myogenic proliferation when 
incubated at 33 o C in the presence ofγ-IFN. Upon switching cell culture conditions to 37 o C and removing γ-IFN 
the H2K SF1 cells exit mitosis and terminally differentiate. Although considered, primary myoblasts from the 
mdx mouse [14][15] were not deemed an appropriate cell model for this study as their limited mitotic capacity 
in vitro would have required repeated isolation of heterogeneous primary myoblasts, which may have increased 
inter-experimental variability.
Here we show the SB system were capable of stably integrating the ΔR4-R23/CTΔ micro-dystrophin gene into 
the genome of the H2K SF1 cells. In addition, genetically corrected H2K SF1 cells retained their myogenic 
potential in vitro and in vivo, suggesting the non viral SB system is a promising non-viral integrating vector for 
the treatment of neuromuscular diseases.
Material and Methods
Cell culture
To encourage cell adhesion, myoblasts were cultured on Martigel (0.1mg/mL, B.D. Bioscience, Matrigel diluted 
in DMEM) coated flasks in proliferating and terminally differentiating conditions. H2K SF1 and the conditionally 
immortal wild-type cell-line, H2K 2B4 [16], were cultured as previously described [12][16]. To initiate terminal 
differentiation H2K SF1 myoblasts were cultured for three days at 37 o C, 5% CO 2  in differentiation medium 
[DMEM, 5% (v/v) Horse Serum, 4mM L-glutamine and 1% penicillin/streptomycin] without γ-IFN, at a seeding 
density of 5×10 4 myoblasts per well in a volume of 250µl (LABTEK eight-well chamber slides, Nunc). Myotubes 
were immunostained as previously described [16] with the following primary antibodies, anti-Pax7 
(Developmental Studies Hybridoma Bank,DSHB), anti-MyoD (clone 5.8A, DakoCytomation), anti-myogenin 
(clone F5D, DSHB), anti-MyHC (clone MF20, DSHB) and T-antigen (EMDA Biosciences). Primary antibodies were 
detected with an appropriate fluorescent secondary antibody. Nuclei were counterstained with DAPI (Invitrogen).
Construction of the pT2/microdys plasmid
The pT2/microdys plasmid consisted of a bicistronic expression cassette in between the terminal repeats of the 
SB transposon [17]. The bicistronic cassette utilised a composite ferritin promoter (MONO) to drive expression 
of the ΔR4-R23/CTΔ micro-dystrophin and neo genes, using an internal ribosome entry site (IRES) to achieve 
similar gene expression levels. To generate the pT2/microdys plasmid, an intermediate plasmid pT2/MONO-neo-
gfp plasmid was constructed. The SB transposon, pT2/BH, and pMONO-neo-gfp (Invivogen) plasmids were 
digested with the EcoRV and SbfI restriction enzymes, respectively. Digested fragments were ligated overnight 
and transformed into chemically competent DH10B E.coli. Purified pT2/MONO-neo-gfp cDNA was digested with 
AvrII and AgeI and simultaneously the pAAVSpc512 ΔR4-R23/CTΔ micro-dystrophin plasmid [11] was digested 
with NotI and EcoRI. To form the pT2/microdys plasmid, pT2/MONO-neo-gfp and ΔR4-R23/CTΔ micro-dystrophin 
cDNA fragments were ligated overnight prior to transforming into chemically competent DH10B E.coli.
pT2/microdys transposition assay
Using Nucleofection (programme B-032, Lonza, Switzerland), 5×10 5 H2K SF1 cells were co-transfected with 
725ng of pT2/microdys and 50ng of the SB 100 transposase plasmids [18] . Forty-eight hours post transfection, 
growth medium was replaced with fresh growth media supplemented with 800µg/mL of G418. Growth media 
supplemented with 800µg/mL G418 was changed every 2-3 days. G418 resistant clones were counted after 14 
days of selection. Integration sites were analysed using the plasmid recovery method [4][16]. Briefly, genomic 
DNA (gDNA) was extracted from H2K SF1 G418 resistant colonies, digested with the SspI enzyme and self 
2PLOS Currents Muscular Dystrophy
ligated using 3U of ligase (Roche) in a total volume of 500 µl at 22°C overnight. Ligated gDNA was 
electroporated into 50µl of ElectroMAX DH10B T1 phage competent bacteria (Invitrogen). Transformed bacteria 
were grown overnight at 30 o C on LB agar plates containing kanamycin (50µg/mL, Sigma). Kanamycin resistant 
colonies were counter selected on LB agar plates supplemented with kanamycin and ampicillin (50µg/mL, 
Sigma). Plasmid DNA was extracted from Kan resistant and Amp sensitive colonies and integrations sites were 
analysed using primers that hybridised to the left and right terminal repeats of the transposon (Left ITR: 
5’GACTTGTGTCATGCACAAAGTAG and Right ITR: 5’CCACTGGGAATGTGATGAAAG [19]). Sequencing reactions 
were analysed using a nucleotide basic local alignment search tool (nBLAST) against the NCBI mouse genome 
database.
Myoblast transplantation
Experiments were conducted under a Home Office project licence following institutional ethical review 
(compatible with Directive 86./609/EEC). To increase myoblast engraftment efficiency three week old mdx 
nu/nu mice were anaesthetised with Hypnorm (fentanyl/fluanisone, VetaPharma Ltd) and Hypnovel (midazolam, 
Roche) and both hindlimbs were irradiated with 18 Gy, as previously described [20]. Three days later the mice 
were anaesthetised with isoflurane (Abbott Laboratories) and the right irradiated tibialis anterior (TA) muscles 
were injected with 5×10 5 genetically modified H2K SF1 cells (total volume of 4µL). The left irradiated tibialis 
anterior (TA) muscles were injected with 5×10 5 unmodified H2K SF1 cells. As a control for engraftment 
efficiency, a mouse was injected with wild-type conditionally immortal cells, H2K 2B4 [16], into both TA 
muscles. Three weeks post transplantation, ΔR4-R23/CTΔ micro-dystrophin protein expression was assayed 
immunocytochemically on 10µm transverse muscle cryosections using the polyclonal P7 antibody (1/1000) [21]
or the MANEX1011c antibody(1/50) [22].
Results
To confirm the H2K SF1 clone represented a good myogenic dystrophin deficient model, the cell-line was 
characterised in vitro. A mdx ARMS PCR assay [23] confirmed the cells harboured the mutated murine DMD 
gene, which fails to produce a functional dystrophin protein. In addition, detection of the thermolabile T-antigen 
protein in proliferating myoblasts (33 o C +γ-IFN) confirmed immortalisation (Figure 1a). The H2K SF1 clone was 
terminally differentiated and expression of myogenic proteins was assessed (Figure 1b-f). Uniform myotubes 
and expression of myogenic proteins verified conditional immortalisation did not inhibit the clone’s myogenic 
capacity. To determine whether the H2K SF1 clone was readily transfectable, 5×10 5 H2K SF1 cells were 
transfected with 2µg of the pMONO-neo-eGFP plasmid using Nucleofection (programme B-032, Lonza, 
Switzerland). Transient expression of the eGFP gene 48 hours post transfection showed 39% (n=4, SEM ±1.30) 
of the myoblasts expressing the transgene.
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Fig. 1: In vitro characterisation of the H2K SF1 cell-line.
A) Expression of the thermolabile T-antigen protein (red, middle column) in proliferating H2K SF1 cells. 
Myogenic protein expression in H2K SF1 myotubes, B) slow& fast myosin, C) Pax7, D) MyoD, E) myogenin 
and F) T-antigen. Myonuclei were counterstained with DAPI (blue, left column). Right column shows the 
merged signals. Scale bars: A&B-50 microns, C, D, E&F -25 microns.
To assess if the SB system was able to successfully transpose the ΔR4-R23/CTΔ micro-dystrophin gene [11][24]
into the genome of the H2K SF1 cell-line, a new SB transposon (pT2/microdys) was constructed. Using 
Nucleofection, myoblasts were either co-transfected with the pT2/microdys transposon and SB100 transposase 
plasmids or with the pT2/microdys plasmid alone (negative control). Co-transfected H2K SF1 cells had a seven 
fold increase in the number of G418 resistant colonies compared to the negative control, indicating 
transposition had occurred (Figure 2a).
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Fig. 2: Stable integration of the ΔR4-R23/CTΔ micro-dystrophin gene.
A) A histogram showing a significant increase in the number of G418 resistant colonies in H2K SF1 cells co-
transfected with pT2/microdys and SB100 transposase plasmids compared to cells transfected only with the 
pT2/microdys plasmid. Error bars generated from SEM, N value of 4. Mann Whitney test, p=0.0286. B) 
Molecular evidence of pT2/microdys transposition in H2K SF1 cells. TA dinucleotides (bold) represent the 
signature integration profile of the SB transposon and the transposon: chromosome junction site.
Transposition of the pT2/microdys transposon was confirmed at a molecular level through the plasmid recovery 
technique (Figure 2b). When terminally differentiated, the genetically modified H2K SF1 cells formed uniform 
myotubes and had similar expression levels of the myogenic regulatory proteins as wild type H2K SF1 cells 
(Figure 3); indicating the stable integration of the ΔR4-R23/CTΔ micro-dystrophin gene did not hinder the cell’s 
myogenic characteristics in vitro.
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Fig. 3: In vitro terminal differentiation of genetically modified H2K SF1 cells Integration of the 
pT2/microdys gene did not alter the myogenic potential of the H2K SF1 cell-line when terminally 
differentiated in vitro.
Images show the expression of the myogenic related proteins A) desmin (red, middle column), B) Pax7, C) 
MyoD and D) myogenin. Myonuclei were counterstained with DAPI (blue, left column). Right column shows 
the merged signals. Scale bars: A & C- 50 microns, B & D-25 microns.
Subsequently, half a million genetically modified H2K SF1 cells were engrafted into right irradiated TA muscles 
of mdx nu/nu mice. Non-treated H2K SF1 cells were transplanted into the contralateral irradiated TA muscle. As 
a control for myoblast engraftment efficiency, a wild type conditionally immortal satellite cell derived cell-line, 
H2K 2B4 [16], was injected into both irradiated TA muscles of an mdx nu/nu mouse. Three weeks after 
engraftment, dystrophin expression was assessed using the P7 and MANEX1110c antibodies [11][21]. As the 
engrafted H2K SF1cells were not otherwise genetically marked, we used a double labelling system to distinguish 
between donor derived ΔR4-R23/CTΔ micro-dystrophin positive myofibres and revertants [25]. Revertants are 
sporadic dystrophin positive myofibres present in muscles of the mdx mouse. These myofibres arise through 
aberrant splicing of the dystrophin mRNA, removing at least the mutated exon and consequently resulting in an 
in-frame mRNA and production of a functional dystrophin protein [25]. We could achieve detection of ΔR4-
R23/CTΔ micro-dystrophin protein as the P7 antibody binds to the rod domain (exon 57), a region not present 
within the ΔR4-R23/CTΔ micro-dystrophin protein. In contrast, the MANEX1011C antibody was raised against 
repeat 1 within the rod domain, which is present in both proteins. Therefore, myofibres detected with both 
antibodies were likely to be revertants, whilst myofibres detected with only the MANEX1011c antibody were 
considered to be of donor origin. An average of 71 ΔR4-R23/CTΔ micro-dystrophin positive fibres was detected 
within two TA muscles engrafted with genetically modified H2K SF1 cells (Figure 4a). No ΔR4-R23/CTΔ micro-
dystrophin positive fibres were detected with the P7 antibody (Figure 4b). In addition, besides a few revertants, 
no dystrophin positive fibres were detected in any of the contralateral TA muscles implanted with untreated 
H2K SF1cells (data not shown). An average of 88 dystrophin positive myofibres was identified with both 
antibodies in TA muscles engrafted with the control H2K 2B4 cells (Figure 4c&d). More importantly, engrafted 
muscles were of normal size and morphology indicating the cells did not form tumours in vivo.
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Fig. 4: Dystrophin restoration in vivo.
A) Images above show ΔR4-R23/CTΔ micro-dystrophin positive myofibres detected with the MANEX1011c 
antibody within mdx nu/nu TA muscles that had been engrafted with genetically modified H2K SF1 cells. B) 
No dystrophin positive myofibres can be seen in serial sections when using the P7 antibody. C&D) 
Dystrophin positive myofibres detected with both antibodies within TA muscles engrafted with wild-type H2K 
2B4 cells. White asterisks indicate same myofibres within serial sections. Myonuclei were counterstained 
with DAPI (blue). Scale bars-50 microns.
Discussion
Utilising their inherent ability to integrate into the genome, Class II DNA transposons are fast becoming ideal 
non-viral integrating tools for gene therapy. The reconstructed transposon, Sleeping Beauty, has been used to 
integrate reporter and therapeutic genes into the genome of target cells [3][5][7][26][27]. We have previously 
shown the SB system is capable of stably integrating a reporter plasmid into the conditionally immortal cell-line 
H2K 2B4 [16]. To further investigate, a proof of concept study was conducted to determine if the transposon 
based vector was capable of stably integrating the ΔR4-R23/CTΔ micro-dystrophin into a dystrophin deficient 
cell-line, H2K SF1. A cell-based transposition assay resulted in a seven fold increase in G418 resistant colonies 
in H2K SF1 cells co-transfected with the SB transposon and SB100 transposase compared to H2K SF1 cells 
transfected with only the SB transposon. Stable integration was confirmed at a molecular level using a plasmid 
recovery method [4][16]. As we have previously reported the SB system integrates randomly within myogenic 
cells [16], we only looked for SB transposition confirmation rather than an integration profile for this study. 
Once we verified genetically modifying the H2K SF1 with the SB system did not alter their ability to terminally 
differentiate in vitro, the cells were engrafted into irradiated TA muscles of mdx nu/nu mice. As a control for 
engraftment efficiency, a wild type conditionally immortal cell-line, H2K 2B4, was injected into irradiated TA 
muscles. Using a double-labelled antibody system, we confirmed ΔR4-R23/CTΔ micro-dystrophin expression in 
vivo. Whilst this experiment confirmed genetically corrected H2K SF1 cells were able to contribute to muscle 
regeneration, the engraftment efficiency was lower than expected. However, this observation may be due to 
the efficiency of the transplantation as the H2K 2B4 cells also regenerated the mdx nu/nu muscles at least three 
times lower than previously noted [16].
Although myobalsts were used for this proof of concept study, it should be highlighted that these cells are not 
an appropriate target cell to treat DMD due to their limited migration in vivo and hence focal muscle 
regeneration [28][29]. In addition, satellite cells and their progeny are not capable of crossing the endothelial 
walls of blood vessels, thus preventing systemic delivery of the cells [30]. An alternative approach is to use 
other stem cells that are relatively easy to isolate pure populations, expand in vitro and can be delivered 
systemically for muscle regeneration [31][32].
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In this study the ΔR4-R23/CTΔ micro-dystrophin gene was chosen over the mini or full length dystrophin cDNA 
as the SB transposition efficiency decreases with the cargo size [33].
Further development to the SB system has resulted in the generation of the SB sandwich transposon which has 
shown to transpose genes up to 10kb [34]. In addition, the modification of another class II DNA transposon, 
PiggyBac [35], resulting in “ ePiggyBac ”, has been shown to efficiently stably integrate inserts up to 18kb in 
human embryonic stem cells [36]. Whilst further work is required to test the efficiency of the SB sandwich and 
ePiggyBac systems in myogenic cells, these studies highlight the possibility of using transposon based DNA 
vectors to stably integrate a mini or full length dystrophin gene into the genome of target cells.
Unlike lentiviral vectors, the SB system has been shown to exhibit a random integration profile in a variety of 
cell types [8][9][37], and is therefore deemed a safer alternative. However, further work is required to develop 
transposons that integrate into safe pre-determined sites within the genome and thus prevent any potential 
insertional mutagenesis.
In conclusion, this study is the first to demonstrate that the SB system is able to transpose in a murine 
dystrophin deficient myogenic cell-line. More importantly, the mobile element was able to successfully integrate 
the therapeutic gene, ΔR4-R23/CTΔ micro-dystrophin into the genome of the H2K SF1 cell-line without hindering 
the cell’s characteristics in vitro or in vivo. Although further optimisation is required to improve the 
transposition efficiency of larger transgenes, the SB system has promising qualities as a non-viral DNA vector 
for the treatment of neuromuscular disorders.
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